MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.00
+0.26
+1.39%
After Hours: 19.00 0 0.00% 17:07 12/03 EST
OPEN
18.80
PREV CLOSE
18.74
HIGH
19.48
LOW
17.85
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
19.48
52 WEEK LOW
3.690
MARKET CAP
1.36B
P/E (TTM)
-10.7151
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2)
Benzinga · 11h ago
Ocular Drug Delivery Technology Market : Technological Advancements to Play a Key Role in Growth 2020-2029 | Alimera Sciences Inc, Valeant Pharmaceuticals International Inc
A consciously conceived and designed business intelligence report titled Global  by Manufacturers, Type, and Application, Forecast to 2029 by discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This report sheds light on the vital developments along with other events happening in the global Ocular Drug Delivery Technology market which is marking on the enlargement and opening doors for outlook growth in the coming years.
marketresearch.biz · 1d ago
Ocular Therapeut Shares Up 93.2% Since SmarTrend's Buy Recommendation (OCUL)
SmarTrend identified an Uptrend for Ocular Therapeut (NASDAQ:OCUL) on August 26th, 2020 at $9.30. In approximately 3 months, Ocular Therapeut has returned 93.23% as of today's recent price of $17.97.
Comtex SmarTrend(R) · 2d ago
Look for Shares of Ocular Therapeut to Potentially Pullback after Yesterday's 5.43% Rise
Ocular Therapeut (NASDAQ:OCUL) traded in a range yesterday that spanned from a low of $15.55 to a high of $16.53. Yesterday, the shares gained 5.4%, which took the trading range above the 3-day high of $15.86 on volume of 603,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 11/25 17:48
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 11/25 12:35
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24 13:12
Ocular Therapeut Up 66.3% Since SmarTrend Uptrend Call (OCUL)
SmarTrend identified an Uptrend for Ocular Therapeut (NASDAQ:OCUL) on July 20th, 2020 at $9.02. In approximately 4 months, Ocular Therapeut has returned 66.28% as of today's recent price of $14.99.
Comtex SmarTrend(R) · 11/24 05:15
Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020.
Business Wire · 11/23 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCUL. Analyze the recent business situations of Ocular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCUL stock price target is 15.50 with a high estimate of 25.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 148
Institutional Holdings: 42.64M
% Owned: 59.73%
Shares Outstanding: 71.39M
TypeInstitutionsShares
Increased
38
3.78M
New
35
-1.11M
Decreased
30
1.58M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.36%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Independent Director
Charles Warden
President/Chief Executive Officer/Director
Antony Mattessich
Chief Financial Officer
Donald Notman
Chief Operating Officer
Patricia Kitchen
Senior Vice President
Christopher White
Other
Michael Goldstein
Independent Director
Jeffrey Heier
Independent Director
Richard Lindstrom
Independent Director
Bruce Peacock
Independent Director
Suh Hong Seung
Independent Director
Leslie Williams
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.